Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Products under Development by Stage of Development | 8 | 1 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Products under Development by Therapy Area | 9 | 1 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Products under Development by Indication | 10 | 1 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Products under Development by Companies | 13 | 2 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Therapeutics Assessment | 15 | 7 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 2 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Companies Involved in Therapeutics Development | 22 | 10 |
| Amgen Inc. | 22 | 1 |
| Astellas Pharma Inc. | 23 | 1 |
| Chiesi Farmaceutici SpA | 24 | 1 |
| Fujimoto Pharmaceutical Corporation | 25 | 1 |
| Krenitsky Pharmaceuticals Inc. | 26 | 1 |
| MedImmune, LLC | 27 | 1 |
| NsGene A/S | 28 | 1 |
| Pfizer Inc. | 29 | 1 |
| Regeneron Pharmaceuticals, Inc. | 30 | 1 |
| Staidson (Beijing) Biopharmaceuticals Co., Ltd. | 31 | 1 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Drug Profiles | 32 | 17 |
| AS-288640100 Drug Profile | 32 | 1 |
| fasinumab Drug Profile | 33 | 3 |
| fulranumab Drug Profile | 36 | 3 |
| Gene Therapy to Activate NGF for Undisclosed Indication Drug Profile | 39 | 1 |
| KP-544 Drug Profile | 40 | 1 |
| MEDI-7352 Drug Profile | 41 | 1 |
| NsG-0202 Drug Profile | 42 | 1 |
| RBM-004 Drug Profile | 43 | 1 |
| Recombinant Protein to Target NGF for Undisclosed Indication Drug Profile | 44 | 1 |
| Small Molecule for Neurotrophic Keratitis Drug Profile | 45 | 1 |
| tanezumab Drug Profile | 46 | 3 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Dormant Projects | 49 | 2 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Discontinued Products | 51 | 1 |
| Beta Nerve Growth Factor (Beta NGF or NGF) Featured News &Press Releases | 52 | 8 |
| May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain | 52 | 1 |
| Mar 31, 2016: Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain | 53 | 1 |
| Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab | 53 | 1 |
| Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors | 53 | 1 |
| Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909 | 54 | 1 |
| Dec 27, 2010: FDA Halts Development Of Regeneron s Pain Drug | 55 | 1 |
| Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program | 55 | 1 |
| Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab | 55 | 1 |
| May 12, 2010: Regeneron Provides Initial Data On REGN475 | 56 | 1 |
| Feb 16, 2010: Pending Results of Phase Ib Trial for Nsg0202 for Alzheimer's Disease in 2010 | 56 | 1 |
| Nov 15, 2008: Nsgene Has Announced That Six Patients with Alzheimer's Disease Have Now Been Implanted with Its Novel Biodelivery Product Nsg 0202 | 57 | 1 |
| Oct 24, 2008: Krenitsky Pharmaceuticals Wants Out Of Deal With Keryx | 57 | 1 |
| Dec 17, 2007: NsGene First To Implant Genetically Modified Cells Into Patients' Brains | 58 | 1 |
| Dec 12, 2007: Nsgene A/S Begins Phase Ib Clinical Trial with Nsg0202 for the Treatment of Alzheimer s Disease | 59 | 1 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |